Drug profile · INN
fidaxomicin
DIFICLIR
fidaxomicin (DIFICLIR) is a dna-directed rna polymerase inhibitor. Route of administration: oral. Current US regulatory status: approved.
Drug details — fidaxomicin
- US status
- approved
- Class
- Alimentary tract and metabolism (A07)
- Route
- ORAL
- Patents
- 0
- Programs
- 0
- Data quality
- 0.84
Quick answer
fidaxomicin (DIFICLIR) is a dna-directed rna polymerase inhibitor. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
DNA-directed RNA polymerase inhibitor
Primary target: DNA-directed RNA polymerase
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | approved | — |
Related & competitor drugs
Frequently asked questions
What is fidaxomicin?
fidaxomicin (DIFICLIR) is a dna-directed rna polymerase inhibitor. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for fidaxomicin?
DIFICLIR is a marketed brand name for fidaxomicin. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of fidaxomicin?
fidaxomicin has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.